The Case for Low Blood Pressure Targets

Area of Science:

• Cardiology
• Clinical Pharmacology
• Public Health

Background:

• Hypertension management has evolved, moving beyond conventional treatment thresholds.
• Clinical trials demonstrate that the benefits of blood pressure (BP) lowering are linked to baseline BP and cardiovascular risk.
• The relative risk reduction per unit of BP lowering may be attenuated in patients with diabetes and chronic kidney disease.

Purpose of the Study:

• To analyze the totality of hypertension clinical trial endpoint data.
• To determine the relationship between BP levels, cardiovascular risk, and the absolute benefit of pharmacological BP lowering.
• To evaluate the rationale for lowering BP treatment initiation thresholds.

Main Methods:

• Comprehensive analysis of hypertension clinical trial endpoint data.
• Examination of cardiovascular risk and mortality reductions associated with pharmacological BP lowering.
• Review of evidence supporting BP management at levels below conventional thresholds.

Main Results:

• Absolute benefit of BP lowering is directly related to BP level and baseline cardiovascular risk.
• Pharmacological treatment shows greater absolute risk reductions in older individuals.
• Benefits are observed at BP levels below the conventional 140/90 mm Hg threshold, including below the SPRINT target (<120 mm Hg).

Conclusions:

• Pharmacological BP lowering provides substantial cardiovascular risk and mortality reductions, even at lower BP levels.
• There is a compelling rationale to lower the threshold for initiating pharmacological intervention for hypertension.
• Maintaining normal BP over time, rather than waiting for levels to exceed 140/90 mm Hg, offers significant risk reduction.